ESRX

What To Make Of Tuesday’s Surprising Market Move

Wall Street clearly made up for the shortened trading week with a broad rally on Tuesday. Here's our new research on 50 stocks in Portfolio Grader More 

It Doesn’t Pay to Pile Into Hedge-Fund Favorites

Hedge funds' holdings flood the news each quarter, but reports such as the Goldman Sachs VIP List aren't necessarily a good source of actionable trade ideas. More 

Investor Alert: Know Before You Buy These 48 Blue Chips

Greetings from the Las Vegas Money Show! before I head off to my next seminar let me update you on our status for 48 blue chip stocks More 

AAPL Is Still Sour; Look for New Opportunities

The markets are in the middle of a strong rally, and a resurgent Apple is helping to lead the way. I still think it's a stock to sell. More 

Should I Buy Rite Aid? 3 Pros, 3 Cons

Rite Aid's turnaround continues to gain traction, but does that make it a solid investment? Decide by looking at RAD's pros and cons. More 

Obesity Pill Qsymia to Be Covered by Express Scripts

Vivus's new new anti-obesity medication Qsymia has been added to Express Scripts coverage, cutting the price for patients by up to two-thirds. More 

Drugstores or Benefit Managers: Who’s Holding the Cards?

CVS and Walgreen reported vastly different quarters today. Is it a sign of where there's money to be made in the future? More